Portola Pharma (PTLA) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Portola Pharmaceuticals (PTLA) PT Raised to $65 at Cowen
August 5, 2015 8:34 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Portola Pharmaceuticals (NASDAQ: PTLA) to $65.00 (from $45.00) following Q2 results. The analyst notes the Andexanet FDA filing is on track for year end.
Nadeau commented, "Portola... More
